Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Evaluating the safety and efficacy of Icotinib administered in 2-month treatments, in patients with metastatic triple-negative breast cancer that have received at least two prior treatments.
Condition or disease
Metastatic Breast Cancer
This is a phase II, multi-center study. Sixty-seven patients are planned to be enrolled. All patients will receive Icotinib 125 mg BID administered for 8 weeks. Patients with a complete response, partial response or stable disease at that time may continue to be treated based on physician discretion. Follow up is then required until resolution or stabilization of any treatment-related toxicity, and patients with stable disease or objective responses must also continue evaluations until survived.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Age 18 years or older
ECOG 0 or 1
Primary or metastatic tumor onfirmed as triple negative
Measurable disease per RECIST version 1.1
normal organ function, including bone marrow function, renal function, liver function, and cardiac function
Two or more prior chemotherapy
signed and dated an informed consent form
Life expectancy of at least 12 weeks
Pregnant or breast feeding
ECOG score ≧2
Uncontrolled medical problems
Hepatic, renal, or bone marrow dysfunction as detailed above
Concurrent malignancy or history of other malignancy within the last five years except as noted above
Patients were unable or unwilling to comply with program requirements